What is claimed:

~~1. A pharmaceutical composition for oral administration comprising: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-lH-pyrazol-l-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide (Lazertinib) or its pharmaceutically acceptable salt as an active ingredient; and a combination of microcrystalline cellulose and mannitol as a diluent.~~

~~2. The pharmaceutical composition of claim 1, wherein a weight ratio of the microcrystalline cellulose to the mannitol is in a range of 1:0.5 to 1:3.~~

~~3. The pharmaceutical composition of claim 1, wherein a weight ratio of the microcrystalline cellulose to the mannitol is in a range of 1:0.9 to 1:3.~~

~~4. The pharmaceutical composition of claim 1, wherein a weight ratio of the microcrystalline cellulose to the mannitol is in a range of 1:0.9 to 1:1.5.~~

~~5. The pharmaceutical composition of claim 1, further comprising: croscarmellose sodium as a disintegrating agent.~~

~~6. The pharmaceutical composition of claim 5, wherein the croscarmellose sodium exists in a range of 2 to 5 wt%, with respect to the total weight of the composition.~~

~~7. The pharmaceutical composition of claim 1, further comprising: magnesium stearate as a lubricant.~~

~~8. The pharmaceutical composition of claim 1, comprising: N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-lH-pyrazol-l-yl)pirimidine-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide or its pharmaceutically acceptable salt as an active ingredient; a combination of microcrystalline cellulose and mannitol as a diluent; croscarmellose sodium as a disintegrating agent; and magnesium stearate as a lubricant.~~

~~9. The pharmaceutical composition of any one of claims 1 to 8, wherein the active ingredient is N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-lH-pyrazol-l-yl)pirimidine-2-ylamino)-~~

~~4-methoxy-2-morpholinophenyl)acrylamide mesylate.~~

~~10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition consists of 5 to 54 wt% of N (5 (4 (4 ((dimethylamino)methyl) 3 phenyl lH pyrazol l yl)pirimidine 2 ylamino) 4 methoxy 2 morpholinophenyl)acrylamide mesylate; 45 to 87 wt% of the combination of microcrystalline cellulose and mannitol; 0.5 to 10 wt% of croscarmellose sodium; and 0.4 to 2 wt% of magnesium stearate.~~

~~11. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition consists of 7 to 46 wt% of N (5 (4 (4 ((dimethylamino)methyl) 3 phenyl lH pyrazol l yl)pirimidine 2 ylamino) 4 methoxy 2 morpholinophenyl)acrylamide mesylate; 50 to 87 wt% of the combination of microcrystalline cellulose and mannitol; 2 to 5 wt% of croscarmellose sodium; and 0.5 to 1.5 wt% of magnesium stearate.~~

~~12. The pharmaceutical composition of claim 9, wherein N (5 (4 (4 ((dimethylamino)methyl) 3 phenyl lH pyrazol l yl)pirimidine 2 ylamino) 4 methoxy 2 morpholinophenyl)acrylamide mesylate is a crystalline form having a PXRD pattern with peaks at 5.614, 12.394, 14.086, 17.143, 18.020, 19.104, 21.585, 22.131, and 22.487°20 ± 0.2°20.~~

~~13. The pharmaceutical composition of claim 9, wherein N (5 (4 (4 ((dimethylamino)methyl) 3 phenyl lH pyrazol l yl)pirimidine 2 ylamino) 4 methoxy 2 morpholinophenyl)acrylamide mesylate is a crystalline form having a differential scanning calorimeter (DSC) thermogram with an endothermic peak at 210 to 230 °C.~~

~~14. The pharmaceutical composition of claim 13, wherein N (5 (4 (4 ((dimethylamino)methyl) 3 phenyl lH pyrazol l yl)pirimidine 2 ylamino) 4 methoxy 2 morpholinophenyl)acrylamide mesylate is a crystalline form having a differential scanning calorimeter (DSC) thermogram with an endothermic peak at 217±2 °C.~~

1. An invention not claimed in any divisional application.